Alethia BioTherapeutics Inc.

Alethia BioTherapeutics Inc.

March 12, 2007 08:30 ET

Alethia Biotherapeutics Inc. Announces Collaborative Agreement With Biosite for Antibody Development in Ovarian Cancer

MONTREAL, QUEBEC--(CCNMatthews - March 12, 2007) - Alethia Biotherapeutics Inc., a privately held biotechnology company, announced today that it has signed an exclusive collaborative agreement with Biosite Incorporated of San Diego for the development of recombinant monoclonal antibodies against validated targets in ovarian cancer. Under the terms of the collaboration, Alethia will provide Biosite with access to highly specific functional targets that will be evaluated as markers for ovarian cancer. In return, Biosite will provide Alethia with monoclonal antibodies for validated disease-specific targets to accelerate Alethia's therapeutic research development.

"We are extremely excited about this partnership with Biosite," said Mario Filion, executive vice president and chief scientific officer of Alethia. "The development of monoclonal antibodies is directly in line with our drug development strategy to provide disease-specific targets for focused therapeutics. The outcome of this collaboration will constitute the first candidate leads to achieve this objective."

Ovarian cancer is the leading cause of death among gynecological cancers and is rarely diagnosed in its early stages. Considering that the five-year survival rate for all stages is only 35 percent to 38 percent, there are urgent needs to develop better tools for earlier detection and for targeted therapies. Alethia has developed a functional genomics approach to identify new and more specific molecular targets that directly address these unmet medical needs. Based on this discovery effort, a diverse collection of highly specific ovarian cancer targets has been prioritized on the basis of their tissue-specific expression profiles and subjected to validation as potential drug targets. Monoclonal antibodies generated against Alethia's specific targets could contribute to improving early detection as well as providing focused therapeutic strategies.

"This agreement is very strategic for our company," said Yves Cornellier, Alethia's president and chief executive officer. "It will further accelerate our migration from a pure discovery platform player to a full product development organization. Furthermore, this transaction, with such a reputable firm, validates not only the quality of the research done internally, but also the high value and potential of our therapeutic targets."

The financial terms of the agreement were not disclosed.

About Alethia Biotherapeutics Inc.

Alethia is a Montreal-based biotechnology company that specializes in the development of focused therapeutic strategies in cancer and cancer-related complications. The Company applies its unique functional genomics platform to identify and validate highly specific disease-related candidate genes in ovarian cancer and severe bone loss. Alethia is also engaged in the preclinical development of a chemosensitizer that will improve the response of tumors to chemotherapeutic drugs in ovarian and colorectal cancer.

Contact Information

  • Alethia Biotherapeutics Inc.
    Yves Cornellier
    President and CEO
    514-858-7666 ext. 206
    514-858-5333 (FAX)
    Cell: 514-951-6621
    ycornellier@alethiabio.com
    or
    Alethia Biotherapeutics Inc.
    Mario Filion, Ph.D.
    Executive VP, CSO
    514-858-7666 ext.207
    514-858-5333 (FAX)
    Cell: 514-233-5021
    mariof@alethiabio.com